Skip to main content
. 2014 Apr 10;9(4):e94637. doi: 10.1371/journal.pone.0094637

Table 3. The 3-year survival rates according to various clinical factors.

Factors 3-y PFS (%) 95% CI P 3-y OS (%) 95% CI P
Gender 0.117 0.118
Male 45.3 36.4–54.2 61.9 53.7–70.1 .
Female 77.8 68–87.6 88.1 80.2–96
Age 0.011 <0.001
≤60 60 51.8–68.2 78.9 71.8–85.3
>60 21.8 8.4–35.2 21.8 8.4–35.2
ECOG performance status 0.109 0.152
0 60.4 48.5–72.3 76.7 66.8–86.6
1–2 52 43.6–60.4 63.9 55.7–72.1
B symptoms 0.122 0.285
Absent 66.8 57.5–76.1 77.9 70.4–85.4
Present 43 32.8–53.2 61.2 51.5–70.9
Serum LDH 0.455 0.202
Normal 57.3 48.8–65.8 70.5 62.7–78.3
>normal 44.7 29.6–59.8 68 58–78
LN involvement 0.005 0.071
Absent 70.8 61.7–79.9 78.3 70.2–86.4
Present 35.2 23.7–46.7 58.7 48.3–69.1
Ann Arbor stage 0.042 0.304
I 68.3 58.6–78 76.2 67.4–85
II 41.3 27.9–54.7 61.7 50.4–73
III–IV 41.7 27.5–55.9 66.7 53.1–80.3
IPI 0.067 0.053
0–1 55.9 47.6–64.2 70.8 63.6–78
2–5 41.7 27.5–55.9 58.3 44.1–72.5
KPI 0.064 0.251
0 66 51.9–80.1 73.5 60–87
1 67.9 58.2–77.6 75.3 66.3–84.3
2 34.4 9.4–59.4 53.5 30.6–76.4
3–4 20.1 4.5–35.7 59.1 46.1–72.1
Lymphocytes 0.286 0.217
Normal 49.3 40.8–57.8 62.5 54.4–70.6
<normal 62.6 47–78.2 86.7 47.3–93.8
Monocytes 0.432 0.861
Normal 51.6 41.5–61.7 69 60.1–77.9
>normal 53.5 42.4–64.6 67.3 57.4–77.2
Serum IL-9 <0.001 0.001
≤3.49 68.7 59.4–78 86 80.6–91.4
>3.49 28.3 18.4–38.2 42.8 31.9–53.7

Abbreviations: PFS, progression-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; LN, local lymph node; IPI, international prognostic index; KPI, Korean prognostic index